JP2007508353A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508353A5
JP2007508353A5 JP2006534713A JP2006534713A JP2007508353A5 JP 2007508353 A5 JP2007508353 A5 JP 2007508353A5 JP 2006534713 A JP2006534713 A JP 2006534713A JP 2006534713 A JP2006534713 A JP 2006534713A JP 2007508353 A5 JP2007508353 A5 JP 2007508353A5
Authority
JP
Japan
Prior art keywords
mol
pharmaceutical composition
cationic liposome
paclitaxel
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006534713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508353A (ja
JP5645340B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/011655 external-priority patent/WO2005039533A1/en
Publication of JP2007508353A publication Critical patent/JP2007508353A/ja
Publication of JP2007508353A5 publication Critical patent/JP2007508353A5/ja
Application granted granted Critical
Publication of JP5645340B2 publication Critical patent/JP5645340B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006534713A 2003-10-15 2004-10-15 活性成分を含有するカチオンリポソームの投与方法 Expired - Fee Related JP5645340B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03023539.4 2003-10-15
EP03023539 2003-10-15
EP04000361 2004-01-09
EP04000361.8 2004-01-09
PCT/EP2004/011655 WO2005039533A1 (en) 2003-10-15 2004-10-15 Method of administering cationic liposomes comprising an active drug

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012159071A Division JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Publications (3)

Publication Number Publication Date
JP2007508353A JP2007508353A (ja) 2007-04-05
JP2007508353A5 true JP2007508353A5 (enExample) 2007-12-06
JP5645340B2 JP5645340B2 (ja) 2014-12-24

Family

ID=34524705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006534713A Expired - Fee Related JP5645340B2 (ja) 2003-10-15 2004-10-15 活性成分を含有するカチオンリポソームの投与方法
JP2012159071A Pending JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012159071A Pending JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Country Status (11)

Country Link
US (1) US20080063699A1 (enExample)
EP (2) EP2286794B8 (enExample)
JP (2) JP5645340B2 (enExample)
AU (1) AU2004283464B8 (enExample)
CA (1) CA2542217C (enExample)
DK (1) DK2286794T3 (enExample)
ES (1) ES2574231T3 (enExample)
HU (1) HUE028648T2 (enExample)
PL (1) PL2286794T3 (enExample)
PT (1) PT2286794T (enExample)
WO (1) WO2005039533A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP5700909B2 (ja) * 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトMediGene AG パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
CN101257891A (zh) * 2005-09-01 2008-09-03 比奥里波克斯公司 包含抗组胺剂以及皮质类固醇的脂质体组合物及其在制备治疗鼻炎以及相关疾病的药物中的用途
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
KR100658436B1 (ko) * 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
RU2448697C2 (ru) * 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
DE602007007618D1 (de) * 2006-05-18 2010-08-19 Univ Muenchen L Maximilians Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス, エルエルシー 膵臓がんの処置方法
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
JP6112512B2 (ja) * 2010-12-01 2017-04-12 レクシ ファーマ インコーポレイテッド 難治性癌を治療するための方法
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
AU2013212068B2 (en) 2012-01-26 2018-02-15 Life Technologies Corporation Methods for increasing the infectivity of viruses
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
DE102013009744A1 (de) * 2013-03-26 2014-10-02 Forschungszentrum Jülich GmbH Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
KR102742522B1 (ko) 2015-09-16 2024-12-12 디에프비 소리아, 엘엘씨 약물 나노입자 전달체 및 이의 제조방법
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017176628A1 (en) 2016-04-04 2017-10-12 Crititech, Inc. Methods for solid tumor treatment
EP3538074B1 (en) * 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
TWI852903B (zh) * 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
JP2020514359A (ja) 2017-03-15 2020-05-21 ディーエフビー ソリア リミテッド ライアビリティ カンパニー タキサンのナノ粒子を用いる皮膚悪性腫瘍処置のための局所療法
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
BR112019023948A2 (pt) 2017-06-09 2020-06-09 Crititech Inc tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas
EP3615004B1 (en) 2017-06-14 2025-02-19 Crititech, Inc. Methods for treating lung disorders
JP7792750B2 (ja) 2017-10-03 2025-12-26 クリティテック・インコーポレイテッド 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND COLD CANCER USING TAXANE NANOPARTICLES
JP2026505783A (ja) * 2023-01-31 2026-02-18 石薬集団中奇制薬技術(石家庄)有限公司 腫瘍を治療するためのパクリタキセルカチオンリポソームの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
DE4430593C2 (de) * 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7314637B1 (en) * 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
HUP0202669A3 (en) * 1999-09-09 2004-06-28 Univ California Cationic liposome delivery of taxanes to angiogenic bloos vessels
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
JP2005534718A (ja) * 2002-06-26 2005-11-17 メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング カチオンキャリヤー系において診断化合物および治療化合物を安定化させる新規方法
ATE444062T1 (de) * 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend

Similar Documents

Publication Publication Date Title
JP2007508353A5 (enExample)
JP5704788B2 (ja) 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ
JP2018528184A5 (enExample)
JP2011144190A (ja) 抗癌剤の効果増強剤
JP6855488B2 (ja) 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット
EP3443962B1 (en) Quinoline derivative for treating gastric cancer
TWI522105B (zh) 偏亞砷酸鈉於治療癌疼痛及炎症之用途
JP2010043115A (ja) 腫瘍転移および癌の治療における5−フルオロウラシルの有効性の増強
CN101687104A (zh) 包括长春氟宁和曲妥单抗的癌症治疗联合疗法
JP2009536956A (ja) 抗癌治療法
JP2008540364A5 (enExample)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
O'Shaughnessy et al. Current status of paclitaxel in the treatment of breast cancer
CN101652138A (zh) 1-取代芳基-2(1h)-吡啶酮化合物的新医药用途
Garattini et al. Perspectives in cancer chemotherapy
Tralongo et al. Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience
JP2006523664A5 (enExample)
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
Kuo et al. Functionalized drug-gene delivery materials to transport inhibitor of apoptosis protein antagonists for tumor malignancy management
CN113993515B (zh) 使用藏红花酸治疗实体肿瘤的方法
EP2826482A1 (en) Novel antitumor agent comprising combination of three agents
KR20140022856A (ko) 치료적 요법
JPWO2022074124A5 (enExample)
JPWO2015152407A1 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
KR20160009677A (ko) 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합